Early enteral administration of a formula (Impact Registered Trademark) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients

Early enteral feeding of the experimental formula was safe and well tolerated in ICU patients. In patients who received the experimental formula, particularly if they were septic on admission to the study, a substantial reduction in hospital length of stay was observed, along with a significant reduction in the frequency of acquired infections.